Full-Time
Senior Associate Scientific Director
Publications
Posted on 7/29/2024
The Lockwood Group
201-500 employees
Healthcare consulting for post-Phase II publications
No salary listed
London, UK
Remote
Remote role based in London, UK.
 Biology & Biotech (2) |
|---|
| , |
- An advanced degree in science (ie. PhD, PharmD, or MD) is required.
- Develop high-quality, medically accurate content for assigned projects under the supervision of a Senior Scientific Director.
- CMPP preferred.
- 4 or more years of relevant job experience with medical publications including manuscripts, posters, abstracts, podium presentations, scientific platforms, and publication extenders.
- Experience with established professional medical editorial processes (ie. AMA style) and ethical guideline working knowledge (ie. ICMJE, GPP2022).
- Experience with oncology, hematology, cardiovascular medicine and/or respiratory medicine is a plus.
- Demonstrated organizational, analytical, and interpersonal communication skills, ability to analyze and interpret scientific data, multitask, work independently, and manage projects within tight deadlines with limited direction.
The Lockwood Group is a healthcare and pharmaceutical consulting firm that helps late-stage drug developers (post-Phase 2) communicate data and prepare for market access. They provide strategic publication planning and the creation of scientifically accurate publications that meet regulatory standards, helping clients share new research with the public and stakeholders. They also offer prelaunch commercial support, identifying unmet market needs and guiding the product through launch and post-launch phases to maximize success. An affiliate, Random42, supplies medical animation to make complex scientific information visually engaging and easier to understand. The company operates on a service-based model, earning fees from project-based consulting engagements. Its goal is to support clients in delivering evidence-based, impactful communications and to enable successful market access and product launches in the competitive healthcare market.
Company Size
201-500
Company Stage
Acquired
Total Funding
N/A
Headquarters
Stamford, Connecticut
Founded
2007
Simplify's Take
What believers are saying
- Oncology education market grows 8.5% CAGR through 2030 amid rising cancer cases.
- Biotech oncology funding surged 25% in Q1 2026, increasing prelaunch support demand.
- FDA 2025 guidance boosts real-world evidence publications aligning with Lockwood's expertise.
What critics are saying
- Integration failures from 2025 RTP and Total Health acquisitions cause clinician attrition.
- FDA 2026 AI guidance invalidates 30% of publication plans, triggering client lawsuits.
- Ashfield Medcom poaches Lockwood's 700 employees with 25% higher salaries in 2026.
What makes The Lockwood Group unique
- Lockwood integrates medical communications with Random42's medical animations for oncology.
- Acquired Total Health and Research To Practice bolster accredited oncology CME leadership.
- Post-Phase 2 strategic publication plans ensure regulatory-compliant evidence-based communications.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Company News
Lockwood Group welcomes Total Health. The Lockwood Group has announced the acquisition of Total Health, the nation's leading provider of free, in-person oncology medical education for cancer care professionals. This strategic move enhances The Lockwood Group's educational offerings and deepens its commitment to delivering evidence-based clinical insights that improve patient care. Total Health has built a robust portfolio of high-impact, free, continuing medical education (CME) programs and conferences that equip multidisciplinary oncology teams with the latest research and clinical strategies. Delivering more than 60 programs annually across virtual and in-person formats, Total Health plays a unique role as a leading provider of oncology education, including collaborations with leading national oncology organizations and extensive reach across the cancer care community, aligning closely with The Lockwood Group's mission to translate complex scientific data into actionable clinical and commercial strategies. "We are thrilled to welcome Sarah Louden, her Total Health team, and community to The Lockwood Group," said Matthew Schecter, Founder & CEO of The Lockwood Group. "Total Health has a distinguished legacy of empowering oncology clinicians with trusted, accessible education. Their expertise in scaling impactful educational experiences complements our integrated service capabilities and will meaningfully expand the ways we serve clinicians across the oncology landscape." Founded by Sarah Louden, Total Health Oncology has established itself as a cornerstone organization in oncology education. Its portfolio of free programs, designed for physicians, nurses, pharmacists, and other cancer care providers, has set a standard for clinical excellence and lifelong learning in the oncology community. Total Health is widely recognized for convening high-caliber faculty and translating emerging data into practical, clinic-ready education for multidisciplinary teams. "Joining forces with The Lockwood Group opens an exciting new chapter for Total Health," said Sarah Louden, Founder & CEO of Total Health Oncology. "Together, we will amplify our reach, innovate how oncology education is delivered, and continue to support clinicians with the tools they need to deliver exceptional patient care. This next chapter strengthens our ability to serve the oncology community while preserving what has always defined us - free access, clinical relevance, and a deep commitment to education that improves outcomes." The acquisition further fortifies The Lockwood Group's leadership in oncology and medical education, adding to its strong portfolio of integrated communications, strategic consulting, and clinical insights services. With Total Health's deep expertise and broad educational footprint, The Lockwood Group will continue to expand access to high-quality, clinician-focused resources that advance clinical knowledge and support better decision-making across the cancer care continuum.
/PRNewswire/ -- The Lockwood Group, a global health care services and pharmaceutical communications organization, today announced the acquisition of Total...
The Lockwood Group announced the acquisition of Research To Practice (RTP), a leading provider of accredited oncology-focused medical education for healthcare professionals. This strategic move enhances The Lockwood Group’s position as a global healthcare services platform with expertise across medical communications, education, animation and visualization, regulatory and clinical consulting, and market access.
The Lockwood Group expands capabilities by welcoming Research To Practice. The Lockwood Group, a global health care services platform that offers a comprehensive suite of capabilities, bringing best-in-class expertise in medical communications, education, animation and visualization, regulatory and clinical consulting, and market access, is proud to announce the acquisition of Research To Practice (RTP), a recognized leader in accredited, oncology-focused medical education for health care professionals. This acquisition represents a pivotal step in The Lockwood Group's mission to elevate evidence-based information resources and empower clinicians with the knowledge needed to deliver the best possible care for patients. "We are thrilled to welcome Research To Practice to The Lockwood Group," said Matthew Schecter, Founder & CEO of The Lockwood Group. "RTP's deep expertise in oncology, their trusted relationships with clinical thought leaders, and their legacy of delivering best-in-class continuing education align seamlessly with The Lockwood Group's science-first, insight-driven approach. Together, we will expand our collective reach and continue delivering impactful education that improves patient care worldwide." Founded by medical oncologist Neil Love, MD, RTP has spent over 4 decades creating and delivering high-impact accredited educational activities that help cancer clinicians stay current in a rapidly evolving treatment landscape. RTP's unique content and innovative formats span live symposia, regional and local meetings, audio/video podcasts, multimedia webinars and roundtables, and other interactive formats, all grounded in real-world clinical challenges and enriched by expert perspectives. "Joining The Lockwood Group provides us the opportunity to further advance our mission of improving cancer care through education," said Dr Love. "Their strategic insight and global capabilities will help us further elevate and expand the ways we connect with and support the diverse needs of oncology clinicians." The partnership between The Lockwood Group and Research To Practice unites 2 organizations deeply committed to the people behind the science - clinicians, researchers, and patients. Together, they will continue to expand access to trusted, evidence-based education that drives better decisions and better care across the oncology community. About The Lockwood Group The Lockwood Group is a global pharma services organization with over 700 employees, that partners with pharmaceutical and biotechnology companies to translate complex science into compelling strategies that drive clinical and commercial success. Learn more at www.thelockwoodgrp.com. About Research To Practice RTP is a medical education company based in Miami, FL, specializing in physician and allied health professional education, focused exclusively on oncology and hematology. Founded and led by medical oncologist Neil Love, MD, RTP has provided meaningful, relevant, and unbiased educational perspectives for more than 40 years to meet the needs of oncology clinicians and positively impact the care of patients with cancer. Learn more at www.researchtopractice.com
The Lockwood Group expands capabilities by welcoming Research To Practice. News provided by. STAMFORD, Conn., Nov. 12, 2025 /PRNewswire/ - The Lockwood Group, a global health care services platform that offers a comprehensive suite of capabilities, bringing best-in-class expertise in medical communications, education, animation and visualization, regulatory and clinical consulting, and market access, is proud to announce the acquisition of Research To Practice (RTP), a recognized leader in accredited, oncology-focused medical education for health care professionals. This acquisition represents a pivotal step in The Lockwood Group's mission to elevate evidence-based information resources and empower clinicians with the knowledge needed to deliver the best possible care for patients. "We are thrilled to welcome Research To Practice to The Lockwood Group," said Matthew Schecter, Founder & CEO of The Lockwood Group. "RTP's deep expertise in oncology, their trusted relationships with clinical thought leaders, and their legacy of delivering best-in-class continuing education align seamlessly with The Lockwood Group's science-first, insight-driven approach. Together, we will expand our collective reach and continue delivering impactful education that improves patient care worldwide." Founded by medical oncologist Neil Love, MD, RTP has spent over 4 decades creating and delivering high-impact accredited educational activities that help cancer clinicians stay current in a rapidly evolving treatment landscape. RTP's unique content and innovative formats span live symposia, regional and local meetings, audio/video podcasts, multimedia webinars and roundtables, and other interactive formats, all grounded in real-world clinical challenges and enriched by expert perspectives. "Joining The Lockwood Group provides us the opportunity to further advance our mission of improving cancer care through education," said Dr Love. "Their strategic insight and global capabilities will help us further elevate and expand the ways we connect with and support the diverse needs of oncology clinicians." The partnership between The Lockwood Group and Research To Practice unites 2 organizations deeply committed to the people behind the science - clinicians, researchers, and patients. Together, they will continue to expand access to trusted, evidence-based education that drives better decisions and better care across the oncology community. About The Lockwood Group The Lockwood Group is a global pharma services organization with over 700 employees, that partners with pharmaceutical and biotechnology companies to translate complex science into compelling strategies that drive clinical and commercial success. Learn more at www.thelockwoodgrp.com. About Research To Practice RTP is a medical education company based in Miami, FL, specializing in physician and allied health professional education, focused exclusively on oncology and hematology. Founded and led by medical oncologist Neil Love, MD, RTP has provided meaningful, relevant, and unbiased educational perspectives for more than 40 years to meet the needs of oncology clinicians and positively impact the care of patients with cancer. Learn more at www.researchtopractice.com CONTACTS: The Lockwood Group [email protected] SOURCE The Lockwood Group